Richard F Pollock (R F Pollock, Richard Pollock)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 55

Top Venues

Journal of medical economics

ClinicoEconomics and outcomes research : CEOR

Advances in therapy

Journal of comparative effectiveness research

Covalence Research Ltd

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Covalence Research Ltd Dec 01 2018

United Kingdom

Senior Health Economist

Ossian Health Economics and Communications GmbH Feb 01 2009 - Nov 30 2018

Switzerland

Health Economist :: Health Economics

Publications

Lars-Olaf Cardell, Thomas Sterner, Waqas Ahmed, Andreas Kallsoy Slættanes, Mikael Svärd, Richard F Pollock
Modelling the impact of sublingual immunotherapy versus subcutaneous immunotherapy on patient travel time and CO 2 emissions in Sweden. Scientific reports 14 (1) (2024)
Hamza Alshannaq, Richard F Pollock, Michael Joubert, Waqas Ahmed, Gregory J Norman, Peter M Lynch, Stéphane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France. Journal of comparative effectiveness research 13 (3) (2024)
Hamza Alshannaq, Richard F Pollock, Michael Joubert, Waqas Ahmed, Gregory J Norman, Peter M Lynch, Stéphane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France. Journal of comparative effectiveness research 13 (3) (2024)
Ji Yoon Kim, Sabrina Ilham, Hamza Alshannaq, Richard F Pollock, Waqas Ahmed, Gregory J Norman, Sang-Man Jin, Jae Hyeon Kim
Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulin. Journal of medical economics (2024)
Hamza Alshannaq, Richard F Pollock, Michael Joubert, Waqas Ahmed, Gregory J Norman, Peter M Lynch, Stéphane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France. Journal of comparative effectiveness research 13 (3) (2024)
Dusica Hadzi Boskovic, Jayne Smith-Palmer, Johannes Pöhlmann, Richard F Pollock, Steve Hwang, David Bruhn
Systematic Literature Review of Studies Reporting Measures of Functional Outcome or Quality of Life in People with Negative Symptoms of Schizophrenia. Patient related outcome measures 15 (2024)
Dusica Hadzi Boskovic, Jayne Smith-Palmer, Johannes Pöhlmann, Richard F Pollock, Steve Hwang, David Bruhn
Systematic Literature Review of Studies Reporting Measures of Functional Outcome or Quality of Life in People with Negative Symptoms of Schizophrenia. Patient related outcome measures 15 (2024)
Lars-Olaf Cardell, Thomas Sterner, Waqas Ahmed, Andreas Kallsoy Slættanes, Mikael Svärd, Richard F Pollock
Modelling the Costs of Sublingual Immunotherapy versus Subcutaneous Immunotherapy Based on Clinical Appointments and Impacts of Patient Travel in Sweden. ClinicoEconomics and outcomes research : CEOR 16 (2024)
Tariq H Iqbal, Nicholas Alexander Kennedy, Anjan Dhar, Waqas Ahmed, Richard F Pollock
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England. Journal of medical economics 27 (1) (2024)
Hamza Alshannaq, Richard F Pollock, Michael Joubert, Waqas Ahmed, Gregory J Norman, Peter M Lynch, Stéphane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France. Journal of comparative effectiveness research 13 (3) (2024)
Tariq H Iqbal, Nicholas Kennedy, Anjan Dhar, Waqas Ahmed, Richard F Pollock
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England. Journal of medical economics (2024)
Fengkui Zhang, Aizong Shen, Waqas Ahmed, Richard F Pollock
A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China. Advances in therapy (2024)
Hamza Alshannaq, Richard F Pollock, Michael Joubert, Waqas Ahmed, Gregory J Norman, Peter M Lynch, Stéphane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France. Journal of comparative effectiveness research (2024)
Lars-Olaf Cardell, Thomas Sterner, Waqas Ahmed, Andreas Kallsoy Slættanes, Mikael Svärd, Richard F Pollock
Modelling the Costs of Sublingual Immunotherapy versus Subcutaneous Immunotherapy Based on Clinical Appointments and Impacts of Patient Travel in Sweden. ClinicoEconomics and outcomes research : CEOR 16 (2024)
Tariq H Iqbal, Nicholas Alexander Kennedy, Anjan Dhar, Waqas Ahmed, Richard F Pollock
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England. Journal of medical economics 27 (1) (2024)
Hamza Alshannaq, Richard F Pollock, Michael Joubert, Waqas Ahmed, Gregory J Norman, Peter M Lynch, Stéphane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France. Journal of comparative effectiveness research 13 (3) (2024)
Lars-Olaf Cardell, Thomas Sterner, Waqas Ahmed, Andreas Kallsoy Slættanes, Mikael Svärd, Richard F Pollock
Modelling the impact of sublingual immunotherapy versus subcutaneous immunotherapy on patient travel time and CO 2 emissions in Sweden. Scientific reports 14 (1) (2024)
Lars-Olaf Cardell, Thomas Sterner, Waqas Ahmed, Andreas Kallsoy Slættanes, Mikael Svärd, Richard F Pollock
Modelling the impact of sublingual immunotherapy versus subcutaneous immunotherapy on patient travel time and CO 2 emissions in Sweden. Scientific reports 14 (1) (2024)
Kristin Grabe-Heyne, Christof Henne, Isaac Odeyemi, Johannes Pöhlmann, Waqas Ahmed, Richard F Pollock
Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK. Journal of medical economics 26 (1) (2023)
Hamza Alshannaq, Greg Cogswell, Richard F Pollock, Waqas Ahmed, Greg J Norman, Peter M Lynch, Stephane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose and intermittently scanned continuous glucose monitoring in people with type 1 diabetes receiving multiple daily insulin injections in Denmark. Diabetes, obesity & metabolism (2023)
Richard F Pollock, Andreas K Slættanes, Henrik Brandi, Tobias Sydendal Grand
A Cost-Utility Analysis of SQ ® Tree SLIT-Tablet versus Placebo in the Treatment of Birch Pollen Allergic Rhinitis from a Swedish Societal Perspective. ClinicoEconomics and outcomes research : CEOR 15 (2023)
Seiji Fukumoto, Tatsunori Murata, Yutaka Osuga, Richard F Pollock
Incidence of Hypophosphatemia After Intravenous Administration of Iron: A Matching-Adjusted Indirect Comparison of Data from Japanese Randomized Controlled Trials. Advances in therapy (2023)
Nicholas A Kennedy, Maureen M Achebe, Patrick Biggar, Johannes Pöhlmann, Richard F Pollock
A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose. International journal of clinical pharmacy (2023)
Shanlian Hu, De-Pei Wu, Jing Wu, Yabing Zhang, Mette Bøgelund, Johannes Pöhlmann, Richard F Pollock
Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China. Patient related outcome measures 14 (2023)
Hamza Alshannaq, John J Isitt, Richard F Pollock, Gregory J Norman, Greg Cogswell, Peter M Lynch, Stéphane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada. Journal of comparative effectiveness research (2023)
Richard F Pollock, Andreas K Slættanes, Henrik Brandi, Tobias Sydendal Grand
A Cost-Utility Analysis of SQ ® Tree SLIT-Tablet versus Placebo in the Treatment of Birch Pollen Allergic Rhinitis from a Swedish Societal Perspective. ClinicoEconomics and outcomes research : CEOR 15 (2023)
Kristin Grabe-Heyne, Christof Henne, Isaac Odeyemi, Johannes Pöhlmann, Waqas Ahmed, Richard F Pollock
Evaluating the cost-utility of intravesical bacillus calmette-guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK. Journal of medical economics (2023)
William J Valentine, Meredith Hoog, Reema R Mody, Mark Belger, Richard F Pollock
Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States. Diabetes, obesity & metabolism (2023)
W J Valentine, M Hoog, R Mody, M Belger, Richard F Pollock
Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the US. Diabetes, obesity & metabolism (2023)
Richard F Pollock, Philip A Kalra, Paul R Kalra, Fozia Z Ahmed
A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose. Advances in therapy 39 (10) (2022)
Johannes Pöhlmann, Klas Bergenheim, Juan Jose Garcia Sanchez, Naveen Rao, Andrew H Briggs, Richard F Pollock
Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts. Diabetes therapy : research, treatment and education of diabetes and related disorders 13 (4) (2022)
Richard F Pollock, Kirsi Norrbacka, Kristina S Boye, Beatrice Osumili, William J Valentine
The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus. Journal of medical economics 25 (1) (2022)
Richard F Pollock, Anjan Dhar, Matthew Johnson
Economic Analysis of Intravenous Iron in Patients with Iron Deficiency Anemia Due to Inflammatory Bowel Disease: Considerations for Clinicians [Letter]. ClinicoEconomics and outcomes research : CEOR 14 (2022)
Richard F Pollock, Suki Shergill, Phuong Lien Carion, Nanette von Oppen, Ion Agirrezabal, Victoria K Brennan
Advances in Delivery of Selective Internal Radiation Therapy (SIRT): Economic and Logistical Effects of Same-Stay Work-Up and Procedure in the Treatment of Unresectable Liver Tumors in England. Advances in therapy (2022)
Shanlian Hu, Limin Liu, Richard F Pollock, Johannes Pöhlmann, Depei Wu, Yabing Zhang
Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose. Journal of medical economics 25 (1) (2022)
Richard F Pollock, Victoria K Brennan, Suki Shergill, Fabien Colaone
A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials. Expert review of anticancer therapy 21 (3) (2021)
Richard F Pollock, Fabien Colaone, Suki Shergill, Victoria K Brennan, Ion Agirrezabal
Effects of Trial Population Selection on Quality of Life and Healthcare Decision-Making: A Systematic Review and Example in the Treatment of Hepatocellular Carcinoma with Radioembolization. ClinicoEconomics and outcomes research : CEOR 13 (2021)
Richard F Pollock, Gorden Muduma
An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland. ClinicoEconomics and outcomes research : CEOR 13 (2021)
Frank Loughnane, Gorden Muduma, Richard F Pollock
Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland. Advances in therapy 37 (3) (2020)
Richard F Pollock, Fabien Colaone, Laura Guardiola, Suki Shergill, Victoria K Brennan
A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. Journal of medical economics 23 (6) (2020)
Richard F Pollock, Patrick Biggar
Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert review of hematology 13 (2) (2020)
Richard F Pollock, William J Valentine, Steven P Marso, Andreas Andersen, Jens Gundgaard, Nino Hallén, Deniz Tutkunkardas, Elizabeth A Magnuson, John B Buse, null null
Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). Applied health economics and health policy 17 (5) (2020)
Richard F Pollock, Gorden Muduma
A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. Journal of medical economics 23 (7) (2020)
Richard F Pollock, Victoria K Brennan, Ralph Peters, Philipp M Paprottka
Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. Expert review of anticancer therapy 20 (11) (2020)
Thomas Walter, Neil S Hawkins, Richard F Pollock, Fabien Colaone, Suki Shergill, Paul J Ross
Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. Journal of cancer research and clinical oncology 146 (10) (2020)
V K Brennan, F Colaone, S Shergill, Richard F Pollock
A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK. Journal of medical economics 23 (12) (2020)
Jayne Smith-Palmer, Karin Cerri, Urbano Sbarigia, Eric K H Chan, Richard F Pollock, William J Valentine, Kristien Bonroy
Impact of Stigma on People Living with Chronic Hepatitis B. Patient related outcome measures 11 (2020)
Richard F Pollock, Gorden Muduma
Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Advances in therapy 36 (8) (2019)
Christian Vogelberg, Eckard Hamelmann, Ulrich Wahn, Anne Domdey, Richard F Pollock, Tobias Sydendal Grand
Cost-Effectiveness Of The SQ® Grass SLIT-Tablet In Children With Allergic Rhinitis: A German Payer Perspective. ClinicoEconomics and outcomes research : CEOR 11 (2019)
Richard F Pollock, Simon R Heller, Thomas R Pieber, Vincent Woo, Jens Gundgaard, Nino Hallén, Maria Luckevich, Deniz Tutkunkardas, Bernard Zinman, null null
Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). Diabetes, obesity & metabolism 21 (7) (2019)
William J Valentine, Kate Van Brunt, Kristina S Boye, Richard F Pollock
Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation. Applied health economics and health policy 16 (3) (2019)
Richard F Pollock, Gorden Muduma
An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Advances in therapy 35 (12) (2018)
Johan Jendle, Åsa Ericsson, Barnaby Hunt, William J Valentine, Richard F Pollock
Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden. Diabetes therapy : research, treatment and education of diabetes and related disorders 9 (1) (2017)
Rhodri Saunders, Michel M R F Struys, Richard F Pollock, Michael Mestek, Jenifer R Lightdale
Patient safety during procedural sedation using capnography monitoring: a systematic review and meta-analysis. BMJ open 7 (6) (2017)
Wendy S Lane, James Weatherall, Jens Gundgaard, Richard F Pollock
Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. Journal of medical economics 21 (2) (2017)

Richard F Pollock.css-eqlu8i{font-size:small;padding-left:4px;} (R F Pollock, Richard Pollock)

Publication Activity (10 Years)

Top Topics

Top Venues

Richard F Pollock (R F Pollock, Richard Pollock)